How mission fuels risk-taking, w/Illumina CEO Francis deSouza
Rapid Response
00:00
Is There Competition in the Cancer Screening Space?
The f t cs argument though, is that by bringing grail back to being part of alumina, that somehow there may be other efforts in this area that will be competitively disadvantaged. Do i understand that right? Yes. So the f t c has, i tin the last forty years, ve been able to successfully challenge a vertical merger. And so what we saw in both the n ip t space and in the kansa therapy selection spaces that competition flourished. We also have a very strong incentive at alumina to make sure competition flourishes"
Transcript
Play full episode
